BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...raises $55M series BOnKure Inc. raised $55 million in a series B round led by Acorn Bioventures...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

...Medical Centre, NIH, Xi’an Jiaotong University Corporate partners: AvectasNumber of employees: 18Funds raised: $16.5 millionInvestors: Acorn Bioventures...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...fund.Neuron23’s series B round included Cowen Healthcare Investments, Acorn Bioventures...
...Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...Pharma Inc.’s  former Head of Europe Chris Nowers as CEO, and raised $8 million from Acorn Bioventures...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...Exchange. The financing was led by new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, Acorn Bioventures...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...includes contributions from Novo Holdings A/S, Eventide Asset Management, Wellington Management Co., Cowen Healthcare Investments, Acorn Bioventures...
Items per page:
1 - 7 of 7
BioCentury | Mar 5, 2021
Deals

March 4 Quick Takes: Crossovers pour into Amunix’s $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA

...raises $55M series BOnKure Inc. raised $55 million in a series B round led by Acorn Bioventures...
BioCentury | Jan 23, 2021
Emerging Company Profile

ONK’s CAR NK cells hit the TRAIL

...Medical Centre, NIH, Xi’an Jiaotong University Corporate partners: AvectasNumber of employees: 18Funds raised: $16.5 millionInvestors: Acorn Bioventures...
BioCentury | Dec 16, 2020
Emerging Company Profile

With crossover funding already in place, Stagliano’s Neuron23 exits stealth with programs in neurology, systemic immune disease

...fund.Neuron23’s series B round included Cowen Healthcare Investments, Acorn Bioventures...
...Kleiner Perkins, Redmile Group, Cowen Healthcare Investments, Acorn Bioventures...
BioCentury | Oct 31, 2020
Deals

Oct. 30 Quick Takes: Q32 raises B round; plus CStone-LegoChem, Centrexion, Sidekick

...Bio Inc. raised $60 million in a series B round led by OrbiMed Advisors and Acorn Bioventures...
BioCentury | Oct 20, 2020
Deals

Oct. 19 Quick Takes: Genesis, Genentech in AI drug discovery deal; plus Endo-BioSpecifics, Gemini, Catalyst-Jacobus, ONK, Venclexta

...Pharma Inc.’s  former Head of Europe Chris Nowers as CEO, and raised $8 million from Acorn Bioventures...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...Exchange. The financing was led by new investors RA Capital Management, Access Biotechnology, Perceptive Advisors, Acorn Bioventures...
BioCentury | Jun 30, 2020
Finance

Syncona’s Freeline mulls IPO after crossovers back gene therapy play

...includes contributions from Novo Holdings A/S, Eventide Asset Management, Wellington Management Co., Cowen Healthcare Investments, Acorn Bioventures...
Items per page:
1 - 7 of 7